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Abstract
High titers of autoantibodies against glutamic acid decarboxylase 65 (GAD65) are commonly
observed in patients suffering from type 1 diabetes (T1D) as well as Stiff Person syndrome (SPS), a
disorder that affects the central nervous system, and a variant of SPS, progressive encephalomyelitis
with rigidity and myoclonus (PERM). While there is a considerable amount of data focusing on the
role of GAD65-specific CD4+ T cells in T1D, little is known about their role in SPS. Here we show
that mice possessing a monoclonal GAD65-specific CD4+ T cell population (4B5, PA19.9G11 or
PA17.9G7) develop a lethal encephalomyelitis-like disease in the absence of any other T cells or B
cells. GAD65-reactive CD4+ T cells were found throughout the CNS in direct concordance with
GAD65 expression and activated microglia: proximal to the circumventricular organs at the interface
between the brain parenchyma and the blood brain barrier. In the presence of B cells, high titer anti-
GAD65 autoantibodies were generated but these had no effect on the incidence or severity of disease.
In addition, GAD65-specific CD4+ T cells isolated from the brain were activated and produced IFN-
γ. These findings suggest that GAD65-reactive CD4+ T cells alone mediate a lethal
encephalomyelitis-like disease that may serve as a useful model to study GAD65-mediated diseases
of the CNS.
INTRODUCTION
Glutamic acid decarboxylase (GAD) catalyzes the conversion of glutamic acid to γ-
aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system
(CNS). There are two different isoforms of GAD, GAD65 and GAD67 that are generated from
two different genes. GAD is expressed in the pancreas and central nervous system and has been
implicated as a target antigen in Type 1 Diabetes (T1D) (1,2), Stiff- Person Syndrome (SPS),
a rare autoimmune disorder thought to occur because of an impairment of GABA production,
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and a variant of SPS, progressive encephalomyelitis with rigidity and myoclonus (PERM)
(3,4).
Autoantibodies against GAD are a hallmark of T1D, with 80% of new-onset T1D patients
showing detectable levels of anti-GAD antibodies prior to clinical onset of disease (5). High
titers of anti-GAD antibodies are also detected in SPS patients suggesting a prominent role of
the GAD antigen in this disease. In fact, there is some suggestion that the anti-GAD antibodies
may inhibit the function of GABA, leading to the neurological symptoms observed in these
patients (6,7). While there is considerable evidence for the presence of anti-GAD antibodies
in SPS and PERM, far less is known about the role and relative importance of GAD reactive
T cells in these diseases.
We had previously generated a number of GAD65-reactive CD4+ T cell hybridomas or clones
from NOD mice either immunized with a series of peptides comprising the major immunogenic
GAD65 epitopes (8,9) or left untreated (10). The TCRs were cloned and expressed using a
retroviral-mediated stem cell gene transfer system (referred to herein as retrogenic [Rg] mice)
in which sublethally irradiated NOD.scid mice were reconstituted with NOD.scid bone marrow
transduced with retrovirus containing a self-cleaving 2A-peptide linked TCR and a green
fluorescent protein (GFP) in the same vector (11–14). Our previous studies have shown that T
cells expressing GAD65-specific TCRs did not mediate diabetes nor cause insulitis (8,9),
consistent with other studies (15). In the present study, we describe the surprising finding that
three of these GAD65-reactive clonotypes (4B5, PA19.9G11 and PA17.9G7) induced a lethal
encephalomyelitis-like disease and ataxia in Rg mice. In addition to detailing these
observations, we also addressed the following questions: (1) Do the GAD65 reactive T cells
infiltrate the CNS and cause inflammation? (2) In the presence of B cells, are GAD65 antibodies
generated and do these affect the disease phenotype? (3) Is there a link between T cell




NOD.scid, NOD.Tcra7−/− and Rag1−/− mice were obtained from The Jackson Laboratory and
bred in-house. B6g7 mice were a gift from C. Benoist and D. Mathis (Harvard Medical School,
Boston, MA). All mice were bred and housed at the St. Jude Animal Resources Center
(Memphis, TN) in a Helicobacter-free SPF facility following state, national and institutional
mandates. The St. Jude Animal Resources Center is accredited by the American Association
for the Accreditation of Laboratory Animal Care. All animal experiments followed animal
protocols approved by the St. Jude Institutional Animal Care and Use Committee.
TCR retroviral constructs
All TCRs were generated as 2A-linked single ORFs using recombinant PCR and cloned into
an MSCV-based retroviral vector with a green fluorescent protein (GFP) marker as previously
described (11,12,14). Details of cloning strategies and primer sequences are available upon
request (vignali.lab@stjude.org). The PA21.14H4, PA19.9G11 and PA17.9G7 TCR were
cloned from hybridomas generated by immunizing NOD mice with HEL 11–25 (PA21.14H4),
GAD 221–237 (PA19.9G11), and GAD 284–300 (PA17.9G7), respectively (8). The 4B5 TCR
was cloned from a GAD65-specific CD4+ T cell clone established from unimmunized 4 wk-
old NOD female mice using recombinant GAD65 protein for in vitro expansion (10). The
PA21.14H4 and 4B5 TCRs have a glycine only linker between the Cα and TaV.2A
(PA21.14H4) or PTV1.2A (4B5) sequence. The PA19.9G11 and PA17.9G7 TCRs have a
glycine-serine-glycine linker between the Cα and PTV1.2A sequences.
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Retroviral-mediated stem cell gene transfer
Retroviral-mediated stem cell gene transfer was performed as previously described (11–14).
Briefly, bone marrow was harvested from the humerus, pelvis, tibia and femur of 5FU treated
mice. The bone marrow was incubated with mIL-3, hIL-6 and mSCF for 48 h and then cultured
on plates seeded with irradiated TCR retroviral producer cells. After 48 h, the transduced bone
marrow was harvested from the plates and 4 × 106 bone marrow cells were injected into the
tail veins of NOD.scid mice that had been irradiated with 300 Rads.
For experiments requiring both T cells and B cells, NOD.scid bone marrow was transduced
with TCR+GFP+ virus and either NOD.Tcrα−/− (B cells) or NOD.scid (control) bone marrow
transduced with vector containing YFP+ only virus. Mice received 2 × 106 NOD.scid TCR
transduced bone marrow and either 2 × 106 NOD.Tcra−/−. YFP+ transduced bone marrow or
2 × 106 NOD.scid YFP+ transduced bone marrow.
Flow cytometric analysis and cell sorting
For flow cytometric analysis, cells were stained with CD4-APC Cy7 or CD4-PE and TCRβ-
APC or TCRβ–PE (BD Biosciences and eBioscience, San Diego, CA). Live, GFP+ cells were
gated for analysis unless otherwise indicated. For analysis of activation markers, cells were
stained with CD69-PerCPCy5.5 (BD Biosciences San Diego, CA). For intracellular cytokine
staining, the spleen or pituitary were teased into a single cell suspension. All cells were
activated with anti-CD3 and anti-CD28 coated beads overnight. Following activation, Golgi
plug (BD Biosciences, San Diego, CA) was added and incubated with the cells for 5.5 h. Cells
were stained with CD4-Cychrome (BD Biosciences, San Diego, CA), fixed and permeablized
with a cytofix/cytoperm solution kit (BD Biosciences, San Diego, CA) and stained with IFN-
γ-APC (BD Biosciences, San Diego, CA). For purification of cells by FACS, splenocytes were
stained with CD4-APC and TCRβ-PE (BD Biosciences and eBioscience, San Diego, CA) and
gated on GFP+CD4+TCR+ cells.
Isolation of lymphocytes from brain
Brains were extracted and homogenized through a 70 μm filter, rinsed with PBS, re-filtered
and centrifuged at 1200 rpm for 5 min. Cells were then resuspended in 70% Percoll (GE
Healthcare) and placed in a 40%–70% Percoll gradient and centrifuged at 2400 rpm for 30 min
with no brake. The interface was collected and washed twice with PBS. The cells were then
stained as outlined above.
Functional assays and cytokine analysis
Functional assays were performed by culturing 2.5 × 104 GFP+CD4+TCR+ cells purified by
FACS with 5 × 105 irradiated NOD splenocytes and a titration of GAD65 whole protein or
peptides (Diamyd, Pittsburg, PA) in 10% FBS-supplemented Eagle’s minimum essential
medium for 48 h. Cells were pulsed with 1μCi of [3H]-thymidine for 24 h and harvested. All
values were corrected for background. Prior to pulsing, 50 μl of supernatant was removed and
analyzed for IL-2, , IL-17 and IFN-γ using a Milliplex kit (Millipore, Billerica, MA) and
Bioplex machine (BioRad, Philadelphia, PA).
Histology
Spleens were harvested and mice perfused with 2.5% paraformaldehyde (Electron Microscopy
Sciences, Hatfield, PA) in PBS pH 7.4. The brain, pituitary and spinal cord were removed from
each mouse and placed in fixative overnight at 4°C. All tissues were cryoprotected in 30%
sucrose in PBS for 3 days, embedded in freezing medium (Triangle Biomedical Sciences,
Durham, NC), flash frozen on dry ice and stored at −80°C for later use. 20μm thick sections
of brain and spinal cord and 10μm sections of pituitary were cut on a HM 560 cryostat (Microm,
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Walldorf, Germany) then thaw-mounted on Superfrost/Plus slides (Fisher Scientific,
Pittsburgh, PA). Sections were air-dried overnight then stored at −20°C. The following primary
antibodies were used: rat anti-CD4 (1:50; eBiosciences, San Diego, CA), rabbit anti-Iba-1
(1:500; Wako Chemicals, Japan) and rabbit anti-GAD65 (1:500; Chemicon, Temecula, CA).
To demonstrate the presence of CD4+ cells in the brains of mice possessing GAD65-reactive
T cells, sagittal sections were treated with anti-CD4 primary then biotinylated goat anti-rat
secondary (1:500; BD Biosciences). Visualization was by diaminobenzidine (DAB) reaction
using Vectastain ABC kit as per manufacturer directions. For double labeling of GAD65 with
CD4, goat anti-rat Alexa Fluor 546 and goat anti-rabbit Alexa Fluor 647 (Invitrogen, Carlsbad,
CA) was used on all tissues. Slides were coverslipped with Prolong Gold Antifade Reagent
with DAPI (Invitrogen) to counterstain nuclei.
GAD65-specific autoantibody detection
GAD65 autoantibodies were measured using a radiobinding assay as previously described
(16,17). Briefly, sera from the TCR retrogenic mice detailed were incubated with [3H]-
thymidine-labeled GAD65 and precipitated with protein A Sepharose (Amersham). The assay
was performed on a 96-well filtration plate (Fisher) and radioactivity was counted on a
Topcount 96-well plate beta counter (PerkinElmer). Antibody levels were expressed as an
index. The inter-assay coefficient of variation is 10% (n=50) for GAD65 autoantibodies. The
upper limits of normal controls (0.032 for GAD65 autoantibodies) were established as the
99th percentile of 198 healthy controls. In the most recent DASP (Diabetes Autoantibody
Standardization Program) workshop, the sensitivity and specificity were 76% and 99%,
respectively, for GAD65 autoantibodies.
RESULTS
GAD65-specific TCRs cause an encephalomyelitis-like disease
In order to investigate the role of GAD65-specific CD4+ T cells in T1D, we had previously
established Rg mice expressing ten different GAD65-specific TCRs (8, 9 and data not shown)).
While none of the GAD65-specific TCRs mediated insulitis or T1D, surprisingly, NOD.scid
Rg mice expressing three of these GAD65-specific monoclonal TCRs, 4B5, PA19.9G11 and
PA17.9G7, developed a lethal encephalomyelitis-like disease (Table I, Fig. 1, A and B). As a
control, Rg mice expressing an H-2Ag7-restricted TCR specific for hen egg lysozyme (HEL)
(PA21.14H4) were used. It is important to note that because retroviral-transduced bone marrow
from NOD.scid mice was used, no additional T or B cells were present in the recipient animals.
Beginning on day 28 post-bone marrow transplant, the mice expressing the GAD65-specific
TCRs, 4B5, PA17.9G7 and PA19.9G11 began to lose weight. Strikingly, weight loss was
followed by symptoms that resemble experimental autoimmune encephalomyelitis (EAE)
including a flaccid tail, abnormal righting reflex, impaired balance, involuntary movements,
paralysis and eventual death (Fig. 1 A). Rg mice expressing the three GAD65-reactive TCRs
exhibited a similar severity and time of onset of disease (Fig. 1, A and B). In contrast,
NOD.scid Rg mice expressing the HEL-specific TCR PA21.14H4 remained asymptomatic. It
is important to note we have never observed diabetes in Rg mice expressing any GAD-specific
TCR in this or previous studies (9, 18 and data not shown). In addition, Rg mice expressing
4B5, PA17.9G7 and PA19.9G11 TCRs did not develop any insulitis nor peri-insulitis.
We also tested the ability of 4B5 to cause disease in a non-autoimmune prone background
using Rag1−/−.B6g7 bone marrow and sub-lethally irradiated Rag1−/−.B6g7 mice as recipients.
This resulted in a disease incidence of 60% with all mice that displayed symptoms progressing
to Grade 5 (Fig. S1). However, this incidence was less than that seen on a NOD.scid
background.
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It was apparent from the symptoms that there was a high probability of encephalopathy in the
experimental animals, therefore we examined brain sections from experimental and control
NOD.scid Rg mice to determine if the GAD65-reactive T cells were infiltrating the brain.
Interestingly, analysis of mouse brain sagittal sections revealed that there were CD4+ T cells
infiltrates throughout the brain of experimental but not control animals (Fig. S2). The location
of the cellular infiltrates in the brain was consistent with the position of the circumventricular
organs, the structures lining the cavity of the third and fourth ventricles where the blood brain
barrier is incomplete. These regions include the pituitary gland, the vascular organ of the lamina
terminalis, the subfornical organ, the pineal gland and the area postrema (19,20). Brains from
control NOD.scid Rg mice expressing the HEL-specific TCR PA21.14H4 were devoid of
CD4+ cells (Fig. S2).
Next, we determined if CD4+ T cell infiltration correlated with areas of GAD65 expression in
the brain. T cell infiltration was localized to the regions within the brain that have been shown
to express GAD65, including the pituitary gland, thalamus (Fig. 1C), olfactory bulb (Fig. S2)
and spinal cord (Fig. S3) (21). CD4+ T cell infiltration induced localized inflammation as
determined by expression of Iba-1, a marker for microglial and macrophage activation
predominantly in the intermediate and posterior lobes of the pituitary gland (Fig. 1C) (22).
Taken together these data suggest that some GAD65-reactive T cells infiltrate the brain in the
absence of B cells and cause localized inflammation concordant with GAD65 expression that
results in a lethal encephalomyelitis-like disease.
GAD-reactive T cell development appears normal
Given the striking phenotype of the GAD65-specific TCR Rg mice, we first verified that 4B5,
PA17.9G7 and PA19.9G11 T cell reconstitution was equivalent by GFP and TCR expression
to the PA21.14H4 HEL-specific control (Fig. 2, A and B). While the percentage and number
of T cells in the spleens of 4B5 and the control PA21.14H4 TCR NOD.scid Rg mice were
comparable, significant reductions were seen in PA17.9G7 and PA19.9G11 Rg mice (Fig. 2,
A and C). While these differences may underlie the basis for the reduced incidence of disease
in PA17.9G7 and PA19.9G11 compared with 4B5 Rg mice (Fig. 1A), the rate of disease onset
and severity was nevertheless comparable in all three GAD-specific TCR Rg mice (Fig. 1, A
and B). The basis for the reduced splenic cellularity is unknown but may be due to inefficient
thymic selection due to the availability of selecting peptides, differential homeostatic
expansion and/or antigen-driven stimulation in the periphery, or partial exertion of central or
peripheral tolerance. The level of TCR expression on the T cells was also slightly lower in
PA17.9G7 and PA19.9G11 compared to 4B5 and the PA21.14H4 control Rg mice (Fig. 2B).
It is important to point out that while there was some variability in the levels and expression
of 4B5, PA17.9G7 and PA19.9G11, all three were broadly equivalent to the other GAD65-
reactive TCRs expressed that did not cause the lethal encephalomyelitis-like disease ((8, 9)
and data not shown)).
GAD-reactive B cells do not alter the disease incidence or severity
In addition to anti-GAD antibodies being a hallmark of T1D, they are also prevalent at high
levels in SPS and are thought to be instrumental in mediating the disease. Thus we determined
if the incidence and/or severity of the encephalomyelitic-like disease observed in 4B5,
PA17.9G7 and PA19.9G11 Rg mice was enhanced by the presence of B cells and potentially
anti-GAD65 antibodies. Accordingly, chimeric Rg mice were generated by transferring a 1:1
ratio of NOD.scid bone marrow transduced with retrovirus containing TCR.GFP and either
NOD.Tcrα −/− bone marrow transduced with YFP only or NOD.scid bone marrow transduced
with YFP only into NOD.scid mice. The NOD.Tcrα −/− mice, which lack expression of the
TCRα chain, fail to develop T cells but not B cells. The chimeric Rg mice expressing 4B5,
PA17.9G7, PA19.9G11 and the control PA21.14H4 TCR that received the YFP transduced
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NOD.Tcrα −/− bone marrow exhibited equivalent numbers of T cells and B cells in the spleen
(Fig. 3A). All of the GAD65-specific TCR chimeric Rg mice which had B cells developed
encephalitic disease that was comparable to B cell-deficient mice. Notably, there were no
differences in the incidence, rate or severity of disease (Fig. 3B).
Histological analysis of sagittal sections of the brain further demonstrated no significant
difference in pathology between Rg mice that receive only T cells versus T plus B cells (Figs.
S2 and S4). While there was no difference in the disease phenotype, B cells infiltrating the
brain and the pituitary gland were clearly detected in the chimeric Rg mice (Fig. 3C and data
not shown). In the pituitary gland, the majority of the cells were found in the intermediate and
posterior lobes. Although the localization of cells was similar, there was a difference in the
number of T cells present in the brain of 4B5 Rg mice deficient of or replete with B cells (Figs.
1C and 3C). Interestingly, the location of B cell infiltrates correlated directly with T cell
localization and GAD65 expression (Fig. 3C). Similar to T cell-only Rg mice, infiltration
resulted in localized inflammation as determined by expression of Iba-1 by activated microglia
and/or macrophages. Finally, we assessed if anti-GAD65 antibodies were generated in the
presence of B cells and GAD65-reactive T cells in the chimeric Rg mice. High titers of anti-
GAD specific antibodies were generated in all three groups compared to the PA21.14H4 + B
cell only control (Fig. 3D). These results suggest that GAD65-reactive T cells alone mediate
an EAE-like disease, and that the presence of B cells and anti-GAD65 antibodies have no
marked effect on the phenotype and severity of the disease.
GAD65-reactive CD4+ T cells in Rg mice exhibit a pro-inflammatory phenotype
Although the GAD-specific 4B5, PA17.9G7 and PA19.9G11 TCR Rg mice described here
develop a lethal encephalomyelitis-like disease, this was not observed with other GAD-specific
TCR Rg mice analyzed previously (8,9). The PA17.9G7 and PA19.9G11 TCRs were cloned
from T cell hybridomas that were generated by immunizing NOD mice with the GAD65
peptides 284–300 and 221–237, respectively (Table I). PA19.9G11 recognizes GAD221–237,
whereas PA17.9G7 exhibits dual specificity for GAD221–237 and GAD284–300. On the other
hand, the GAD65-specific 4B5 CD4+ T cell clone was established from unimmunized NOD
mice using recombinant GAD65 in vitro, and is specific for both the GAD217–236 and
GAD290–309 peptides (10,23). While CD4+ T cells from 4B5, PA17.9G7 and PA19.9G11 Rg
mice proliferated strongly to their respective peptides, only 4B5 and PA17.9G7 Rg T cells
proliferated in response to GAD65 protein (Fig. 4A and unpublished data). Interestingly,
whereas the three CD4+ T cell populations produced comparable amounts of IL-2, 4B5 and
PA19.9G11 produced significant amounts of IFN-γ upon stimulation with GAD65 protein in
vitro, and 4B5 and PA17.9G7 produced IL-17 (Fig. 4B).
We next determined if the GAD65-specific T cells were activated and secreting IFN-γ in the
brain and pituitary of TCR Rg mice. T cells in the brain and pituitary expressed elevated levels
of CD69, indicating an activated phenotype (Fig. S5). Furthermore, an increased frequency of
GAD65-specific CD4+ T cells expressing intracellular IFN-γ was detected in the brain and
pituitary of 4B5 and PA19.9G11 TCR Rg mice (Fig. 4, C and D). These results suggest that
CD4+ T cells expressing the 4B5, PA17.9G7 and PA19.9G11 clonotypic TCRs recognize
GAD65 in the brain and pituitary, and exhibit a pro-inflammatory phenotype.
DISCUSSION
GAD is a critical enzyme involved in the production of GABA, the main inhibitory
neurotransmitter in the CNS, and is a primary target for autoantibodies in patients suffering
from SPS and PERM. These patients present with symptoms ranging from muscular rigidity
and superimposed spasms, stiff limbs and progressive encephalomyelitis with rigidity (24).
However, with the exception of a few publications (25–28), little information is available on
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the extent of T cell involvement in SPS and PERM despite reports of lymphocyte infiltration
into the CNS of these patients (29,30).
While the fortuitous discovery that certain GAD65-reactive CD4+ T cell populations can cause
a lethal encephalomyelitis-like disease in mice was important, the phenotype of the disease
versus the clinical features of PERM/SPS is different. However this may be the consequence
of anti-GAD TCR clonality in the Rg system and/or the severity and rapid, lethality of the
disease, which may supersede the typical clinical features associated with PERM/SPS.
Consequently, the GAD65-reactive CD4+ T cell-induced encephalomyelitis-like disease may
provide some insight into the encephalomyelitis observed in PERM. The three GAD65-specific
T cell clonotypes, 4B5, PA17.9G7 and PA19.9G11, infiltrated the brain, secreted IFN-γ and
mediated inflammation as determined by microglial activation resulting in a lethal
encephalomyelitis-like disease. Although seen throughout the CNS, the primary sites of T cell
infiltration were localized in and around the GAD positive GABAergic cells located proximal
to the circumventricular organs, where there is an interface between the brain parenchyma and
the blood (19,20). Additionally, throughout the experiments it appeared that the number of
CD4+ T cells as well as the depth of their penetration into the parenchyma increased with
disease progression. However further analysis is required to validate these observations. We
also found that the encephalomyelitic disease was mediated in the absence of B cells and
importantly GAD65-specific autoantibodies. Indeed, despite high titers of anti-GAD65
autoantibodies in B cell-replete chimeric Rg mice, no significant differences were detected in
disease frequency or severity relative to B cell-deficient Rg mice. Taken together these findings
show that GAD65-specific autoantibodies are neither required nor participate in mediating the
lethal encephalomyelitis-like disease observed in GAD65-specific Rg mice. It is tempting to
speculate, that the high titer GAD65-specific autoantibodies seen in PERM patients may not
be the only contributors to disease onset or progression and that perhaps GAD65-specific T
cells may also play a role in mediating pathology at sites were GABAergic cells are located.
It is currently unclear why T cells expressing these three particular GAD65-specific TCRs
mediate the lethal encephalomyelitic disease observed whereas other GAD65-specific TCR
Rg mice that we have previously analyzed fail to develop this disease ((8,9) and data not
shown). There are four possibilities. First, it is interesting to note that with the exception of
one TCR, PA19.9G11, PA17.9G7 and 4B5 were the only TCRs from a panel of 10 GAD65-
specific TCR that recognize the 217–236 epitope. The other TCR, 1A4, not studied in detail
here as it is expressed poorly, caused an encephalomyelitic disease albeit at a reduced incidence
compared to PA19.9G11, PA17.9G7 and 4B5 (data not shown). This suggests that GAD65
217–237 may represent a key immunogenic epitope in the disease. Second, 4B5 and PA17.9G7
TCRs, which were particularly pathogenic, share the unusual feature of exhibiting dual
specificity (GAD 217–236/GAD 290–309 and GAD 221–237/GAD 284–300 respectively),
which might contribute to their escape from tolerance and their ultimate pathogenicity. Third,
relatively few of the GAD65-specific Rg T cell populations we have tested respond strongly
to the whole GAD65 protein. However, it seems less likely that this alone is a deciding factor
as 4B5, PA17.9G7 and PA19.9G11 Rg T cells exhibit quite different reactivities to GAD65
protein despite mediating comparable levels of disease incidence and severity (Figs. 1 and
4A). Lastly, it is important to note that the avidity/affinity of the respective TCRs could be a
key determinant in regulating T cell pathogenicity. For example, GAD65-specific T cell clones
exhibiting poly-specificity appear to express TCR with increased avidity/affinity relative to
mono-specific TCRs (23). It is clear that more studies will be required to establish a link
between epitope specificity, TCR avidity/affinity and/or GAD protein reactivity, and disease
pathogenicity. It is noteworthy that the versatility of the TCR Rg system provides an ideally
flexible and powerful platform to test these issues in the future (9,11,12).
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In summary, we show for the first time that GAD65-specific CD4+ T cells directly mediate
pathology in the CNS leading to a lethal encephalomyelitis-like disease. This system may
represent a useful model for studying GAD65-related CNS diseases. Furthermore, given that
GAD65-specific T cells have been observed in T1D patients, our observations question
whether these might be implicated in some of the neurological complications that are
occasionally observed in T1D patients. In addition, there has recently been increased interest
in the potential use of antigen-specific therapies in T1D. Even though a recent trial involving
GAD immunization did not report any SPS-like observations (31), our data suggest that caution
should be exercised in the use of any therapy involving GAD or GAD-specific T cells.
Supplementary Material
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GAD65-reactive CD4+ T cells cause a lethal encephalomyelitis-like disease. A, Incidence of
disease in NOD.scid mice transplanted with bone marrow transduced with retrovirus encoding
the TCR listed. B, Disease severity as determined by disease score. An EAE-based scoring
system was used to measure disease severity: 0 - normal; 1 – lethargic, ruffled fur, weight loss
of at least 10%, flaccid tail; 2 – 1 plus abnormal righting reflex; 3 – impaired balance and/or
ataxia, involuntary movements, weakness or stiffness of limbs, usually asymmetric; 4 –
paralysis and/or persistent tremors, possible incontinence; 5 – moribund or death (32). The
number of mice followed for incidence is as follows: PA21.14H4 (9), 4B5 (17), PA19.9G11
(8), and PA17.9G7 (11) while 5 mice from each group were monitored for disease score as
outlined in the materials and methods section. C, Pituitary (upper panel) and thalamus (lower
panel) sections of mice with a Grade 3 score (Grade 0 for PA21.14H4) were stained with either
anti-mouse CD4 (red), anti-GAD65 (green) and DAPI (blue), or anti-Iba-1 (green) and DAPI
(blue). The diagrams on the right side depict the anterior (Ant), intermedia (Int) and posterior
(Post) regions of the pituitary gland (upper panel) and a sagittal section of a brain and the
location of the thalamus (lower panel). Data is representative of 6 experiments with 8–17 mice
per TCR group.
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T cell reconstitution is equivalent between Rg mice expressing GAD65-specific and control
TCRs. A, Representative flow cytometric plot illustrating GFP+TCR+ cells (top panel) and
CD4+TCR+ cells (bottom panel) in the spleens of representative TCR NOD.scid Rg mice. The
GFP+TCR+ plots were gated on live cells and the CD4+TCR+ plots were gated on live,
GFP+ cells. B, Mean fluorescence of TCR expression of GFP+ cells in spleens of Rg mice
represented in A. C, Number of GFP+TCR+CD4+ cells in the spleens of TCR Rg mice
represented in A. Data is representative of 6 experiments with 4–11 mice per TCR group.
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The presence of B cells and GAD65 autoantibodies in Rg mice has no effect on the disease
mediated by GAD65-specific CD4+ T cells. A, Number of CD4+ T cells and CD19+ B cells in
spleens of chimeric Rg mice receiving NOD.scid bone marrow transduced with retrovirus
encoding the TCR and either NOD.Tcra−/− or NOD.scid bone marrow transduced with
retrovirus encoding YFP only. Numbers were determined by gating on live, GFP+ (T cells) or
YFP+ (B cells) cells. B, Left panel depicts incidence of disease and right panel indicates disease
severity of chimeric Rg mice receiving 2 × 106 TCR retroviral-transduced bone marrow cells
from NOD.scid and vector transduced bone marrow from either NOD.scid (T-cells alone) or
NOD.Tcra−/− (T cells + B cells) mice. The T cells alone group is depicted as closed symbols
and the T cells plus B cells group is depicted as open symbols with a dashed line. The number
of mice followed for incidence is as follows: PA21.14H4 (4), PA21.14H4 + B cells (7), 4B5
(7), 4B5 + B cells (15), PA19.9G11 (4), PA19.9G11 + B cells (10), PA17.9G7 (5) and
PA17.9G7 + B cells (8) while 5 mice from each group were monitored for disease score as
outlined. C, Pituitary gland sections from NOD.scid mice receiving 4B5- or PA19.9G11-
transduced NOD.scid bone marrow plus NOD.Tcra−/− YFP only transduced bone marrow,
and an unmanipulated NOD.scid mouse as control. Sections were stained with anti-mouse CD4
(T cells), anti-mouse CD19 (B cells), anti-mouse GAD65 (GAD65) or anti-mouse Iba-1
(activated macrophages/microglial) (green) and counterstained with DAPI (blue). Mice in the
4B5 + B cells and PA19.9G11 + B cells groups displayed clinical signs of disease at the time
of euthanasia. D, GAD65-specific autoantibody titres in serum from the chimeric Rg mice at
various states of disease are depicted. Data is representative of 4 experiments with 4–15 mice
per TCR group.
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GAD65-specific CD4+ T cells isolated from the brain are activated and secreting IFN-γ. A,
Reactivity of GFP+CD4+ splenic T cells (2.5 × 104) purified by FACS to GAD65 whole protein
was determined in the presence of 5 × 105 irradiated APCs for 48 hr, pulsed with [3H]-
thymidine and harvested 24 hrs later. Background counts were subtracted from the data
depicted. B, Concentration of IL-2, IFN-γ and IL-17 in supernatants of cells depicted in A
following incubation with 10μg/ml GAD65. C, Representative flow cytometric plots of
CD4+ IFN-γ+ cells in the spleen, brain and pituitary of 4B5 and PA19.9G11 retrogenic mice
displaying a disease score of 3 which was six weeks post transplant. Plots were gated on
GFP+ cells. D, Percentage of GFP+CD4+IFN-γ+ cells in brains of 4B5 and PA19.9G11 Rg
mice six weeks post transplant, displaying a disease score of 3. For A and B data is
representative of 2 experiments with spleens and lymph nodes of 3–4 mice pooled for each
TCR. For C and D data is representative of 4 experiments with 4 mice for each TCR.
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Table I
GAD specific T cell receptors
TCR Name Antigen Specificity
TCR Usage
TCR generated from NOD mice by:Vα Vβ
PA17.9G7 GAD221–237 & GAD284–300 4.5 10 Immunization-GAD284–300
PA19.9G11 GAD221–237 17.1 5.2 Immunization-GAD221–237
4B5 GAD217–236 & GAD290–309 2.4 6 Unimmunized Mice
PA21.14H4 HEL11–25 13.1 6 Immunization with HEL 11–25
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